12938083	207	Eng C	PTEN: one gene, many syndromes.	Human mutation	2003	184
19487299	207	Ricarte-Filho JC	Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.	Cancer research	2009	123
21596819	238	Murugan AK	Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.	Cancer research	2011	42
25500544	238	Yoshihara K	The landscape and therapeutic relevance of cancer-associated transcript fusions.	Oncogene	2015	56
12970315	673	Namba H	Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.	The Journal of clinical endocrinology and metabolism	2003	78
16174717	673	Xing M	BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.	The Journal of clinical endocrinology and metabolism	2005	147
17717450	673	Kebebew E	The prevalence and prognostic value of BRAF mutation in thyroid cancer.	Annals of surgery	2007	69
17785355	673	Lupi C	Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.	The Journal of clinical endocrinology and metabolism	2007	60
17940185	673	Xing M	BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.	Endocrine reviews	2007	186
18310287	673	Frasca F	BRAF(V600E) mutation and the biology of papillary thyroid cancer.	Endocrine-related cancer	2008	54
18682506	673	Elisei R	BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.	The Journal of clinical endocrinology and metabolism	2008	92
19255327	673	Kloos RT	Phase II trial of sorafenib in metastatic thyroid cancer.	Journal of clinical oncology 	2009	123
19414674	673	Xing M	BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.	Journal of clinical oncology 	2009	47
19861538	673	Riesco-Eizaguirre G	The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.	Cancer research	2009	48
19883729	673	Xing M	Prognostic utility of BRAF mutation in papillary thyroid cancer.	Molecular and cellular endocrinology	2010	41
21274720	673	Schindler G	Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.	Acta neuropathologica	2011	134
21882184	673	Kim TH	The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.	Cancer	2012	60
22012135	673	Capper D	Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases.	Acta neuropathologica	2012	40
22105174	673	Chakravarty D	Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.	The Journal of clinical investigation	2011	59
22355009	673	Hong DS	BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency.	Clinical cancer research 	2012	36
22508706	673	Guerra A	A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.	The Journal of clinical endocrinology and metabolism	2012	30
22608338	673	Falchook GS	Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.	Lancet	2012	179
22932786	673	Tufano RP	BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.	Medicine	2012	46
22941165	673	Howell GM	BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer.	Annals of surgical oncology	2013	27
23055546	673	Li C	BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.	The Journal of clinical endocrinology and metabolism	2012	36
23066120	673	Elisei R	The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.	The Journal of clinical endocrinology and metabolism	2012	34
23571588	673	Xing M	Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.	JAMA	2013	123
24617711	673	Liu X	TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.	The Journal of clinical endocrinology and metabolism	2014	41
24768112	673	Brose MS	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.	Lancet	2014	112
25024077	673	Xing M	BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.	Journal of clinical oncology 	2014	57
25332244	673	Xing M	Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.	Journal of clinical oncology 	2015	48
25353071	673	Dadu R	Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.	The Journal of clinical endocrinology and metabolism	2015	17
26287849	673	Hyman DM	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.	The New England journal of medicine	2015	128
26733501	673	Liu R	TERT promoter mutations in thyroid cancer.	Endocrine-related cancer	2016	13
23979959	1499	Nikiforova MN	Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.	The Journal of clinical endocrinology and metabolism	2013	52
17283074	1956	Hsu SC	Characterization of a novel tripartite nuclear localization sequence in the EGFR family.	The Journal of biological chemistry	2007	83
19234440	1956	Inamura K	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.	Modern pathology 	2009	103
20022809	1956	Mitsudomi T	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.	The Lancet. Oncology	2010	783
20065189	1956	Wells SA Jr	Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.	Journal of clinical oncology 	2010	95
22237264	1956	Sun PL	High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.	Journal of thoracic oncology 	2012	34
23123196	1956	Yang W	EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis.	Molecular cell	2012	55
24327398	2120	Leeman-Neill RJ	ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer.	Cancer	2014	25
25295501	2475	Wagle N	Response and acquired resistance to everolimus in anaplastic thyroid cancer.	The New England journal of medicine	2014	61
19934298	2668	Wells SA Jr	Targeting the RET pathway in thyroid cancer.	Clinical cancer research 	2009	45
25807286	2778	Gudbjartsson DF	Large-scale whole-genome sequencing of the Icelandic population.	Nature genetics	2015	98
26222560	3026	Gara SK	Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer.	The New England journal of medicine	2015	19
2547513	3265	Bos JL	ras oncogenes in human cancer: a review.	Cancer research	1989	956
12727991	3265	Nikiforova MN	RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.	The Journal of clinical endocrinology and metabolism	2003	103
21325462	3265	Moura MM	High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.	The Journal of clinical endocrinology and metabolism	2011	37
22241789	3265	Hayes DN	Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.	Clinical cancer research 	2012	36
23264394	3265	Agrawal N	Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.	The Journal of clinical endocrinology and metabolism	2013	34
23954893	3417	Chaturvedi A	Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.	Blood	2013	43
18474871	3654	Jazdzewski K	Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma.	Proceedings of the National Academy of Sciences of the United States of America	2008	224
20368568	3791	Lam ET	Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.	Journal of clinical oncology 	2010	61
24002501	3791	Elisei R	Cabozantinib in progressive medullary thyroid cancer.	Journal of clinical oncology 	2013	116
11459867	3845	Adjei AA	Blocking oncogenic Ras signaling for cancer therapy.	Journal of the National Cancer Institute	2001	157
23668556	3958	Xing M	Progress in molecular-based management of differentiated thyroid cancer.	Lancet	2013	73
19822006	4595	Half E	Familial adenomatous polyposis.	Orphanet journal of rare diseases	2009	81
21880806	4893	Nikiforov YE	Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples.	The Journal of clinical endocrinology and metabolism	2011	95
23406027	4893	Ho AL	Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.	The New England journal of medicine	2013	83
16288007	5290	García-Rostán G	Mutation of the PIK3CA gene in anaplastic thyroid cancer.	Cancer research	2005	81
19318445	5468	Nikiforov YE	Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules.	The Journal of clinical endocrinology and metabolism	2009	103
20099311	5468	Ohori NP	Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance".	Cancer cytopathology	2010	41
19293268	5573	Bertherat J	Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes.	The Journal of clinical endocrinology and metabolism	2009	70
9467011	5728	Marsh DJ	Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation.	Human molecular genetics	1998	118
20600018	5728	Heald B	Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers.	Gastroenterology	2010	42
22252256	5728	Tan MH	Lifetime cancer risks in individuals with germline PTEN mutations.	Clinical cancer research 	2012	93
23335809	5728	Bubien V	High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome.	Journal of medical genetics	2013	30
24136893	5728	Pilarski R	Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria.	Journal of the National Cancer Institute	2013	41
8099202	5979	Mulligan LM	Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.	Nature	1993	182
12670889	5979	Kimura ET	High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.	Cancer research	2003	259
12881714	5979	Soares P	BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.	Oncogene	2003	101
15982921	5979	Arighi E	RET tyrosine kinase signaling in development and cancer.	Cytokine and growth factor reviews	2005	69
18073307	5979	Elisei R	Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.	The Journal of clinical endocrinology and metabolism	2008	56
20130073	5979	Cantara S	Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology.	The Journal of clinical endocrinology and metabolism	2010	51
21878896	5979	Nikiforov YE	Molecular genetics and diagnosis of thyroid cancer.	Nature reviews. Endocrinology	2011	126
24248188	5979	Jung CK	The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations.	The Journal of clinical endocrinology and metabolism	2014	49
15328326	6390	Neumann HP	Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.	JAMA	2004	131
12588808	6528	Dohán O	The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance.	Endocrine reviews	2003	134
23766237	7015	Liu X	Highly prevalent TERT promoter mutations in aggressive thyroid cancers.	Endocrine-related cancer	2013	68
23887589	7015	Vinagre J	Frequency of TERT promoter mutations in human cancers.	Nature communications	2013	120
24141777	7015	Liu T	The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.	Oncogene	2014	43
24476079	7015	Melo M	TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.	The Journal of clinical endocrinology and metabolism	2014	49
17982442	7080	Weir BA	Characterizing the cancer genome in lung adenocarcinoma.	Nature	2007	411
26605532	7157	Jin W	Genome-wide detection of DNase I hypersensitive sites in single cells and FFPE tissue samples.	Nature	2015	31
18390968	22882	Adjei AA	Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.	Journal of clinical oncology 	2008	161
23489023	22882	Kim KB	Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.	Thyroid 	2013	43
21266384	23405	Slade I	DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome.	Journal of medical genetics	2011	59
